Vanda Pharmaceuticals Inc.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $216.1M
- Net income
- -$220.5M
- Total assets
- $488.9M
- Market cap
- $362.6M
- Operating margin
- -70.0%
- Net margin
- -102.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $216.1M
- Operating expenses
- $367.3M
- Operating income
- -$151.2M
- Income tax
- $81.8M
- Net income
- -$220.5M
- EPS (basic)
- $-3.74
- EPS (diluted)
- $-3.74
Balance sheet
- Total assets
- $488.9M
- Current assets
- $347.3M
- Total liabilities
- $161.8M
- Current liabilities
- $145.2M
- Shareholders’ equity
- $327.2M
Cash flow
- Operating cash flow
- -$109.4M
- Investing cash flow
- $94.9M
- Financing cash flow
- -$2.9M
- Net cash flow
- -$17.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $362.6M
- EPS (diluted)
- $-3.74
- Shares outstanding
- 61.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 12, 2006
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $220.5M in FY2025.
- Revenue declined 13% from FY2020 to FY2025.
- Trading 38% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vanda Pharmaceuticals Inc..
Write a review
News about Vanda Pharmaceuticals Inc.
News & sentiment via Polygon.io
